Current management strategies for coexisting diabetes mellitus and obesity

Drugs

Volumn 63, Issue 12, 2003, Pages 1165-1184

  Scheen, Andre J ^a,b  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENFLUOREX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; DEXFENFLURAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENFLURAMINE; FLUOXETINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VOGLIBOSE;

BARIATRIC SURGERY; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC DIET; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; EXERCISE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; LIVER TOXICITY; LONG TERM CARE; LOW CALORY DIET; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; TREATMENT FAILURE; TREATMENT PLANNING; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

DIABETES MELLITUS; DIABETIC DIET; ENERGY METABOLISM; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; OBESITY; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; UNITED STATES; WEIGHT LOSS;

EID: 0038575814     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363120-00001     Document Type: Review

References (200)

1. Scheen AJ. Obesity and diabetes. In: Kopelman PG, editor. The management of obesity and related disorders. London: Martin Dunitz Ltd, 2001: 11-44
2. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-34
3. Screen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology, oral antidiabetics. Berlin: Springer Verlag, 1996: 7-42
4. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity and health risk. Arch Intern Med 2000; 160: 898-904
5. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 7: 761-811
6. Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effects on patients' risk. Obes Res 1998; 6 Suppl. 1: 8S-17S
7. Scheen AJ, Lefèbvre PJ. Insulin resistance versus insulin deficiency: which one comes first? The old question revisited. In: Di Mario U, Leonetd F, Pugliese G, et al., editors. Diabetes in the new millennium. New York: Wiley & Sons, 2000: 101-13
8. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
9. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23: 754-8
10. Newburgh L. Control of hyperglycaemia of obese 'diabetics' by weight reduction. Ann Intern Med 1942; 17: 935-42
11. Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995; 3: 366-77
12. Brown SA, Upchurch S, Anding R, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19: 613-24
13. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744-66
14. Campbell L, Rössner S. Management of obesity in patients with Type 2 diabetes. Diabetic Med 2001; 18: 345-54
15. Williams KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000; 2: 121-9
16. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006-35
17. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-504
18. Screen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7: 77-93
19. Hu FB, van Dam RM, Liu S. Diet and risk of type 2 diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44: 805-17
20. Franz MJ. Lifestyle modifications for diabetes management. Endocrinol Metab Clin North Am 1997; 26: 499-510
21. Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30: 883-907
22. Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002; 25: 1722-8
23. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes in women. N Engl J Med 2001; 345: 790-7
24. Tuomilehto J, Lindström J, Ericksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
25. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
26. Gumbiner B. Treating obesity in type 2 diabetes: calories, composition, and control. Diabetes Care 1999; 22: 886-8
27. American Diabetes Association. Position statement: nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 2001; 24 Suppl. 1: S44-7
28. Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res 2001; 9 Suppl. 4: 348S-53S
29. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1: 113-9
30. Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-6
31. Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 1995; 12: 409-15
32. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415
33. Bosello O, Armellini F, Zamboni M, et al. The benefits of modest weight loss in type II diabetes. Int J Obes Relat Metab Disord 1997; 21 Suppl. 1: S10-3
34. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-53
35. Ross R, Freeman JA, Janssen I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev 2000; 28: 165-70
36. Gautier JF, Scheen A, Lefèbvre PJ. Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Int J Obes 1995; 19 Suppl. 4: S58-61
37. American Diabetes Association. Position statement: diabetes mellitus and exercise. Diabetes Care 1998; 21 Suppl. 1: S40-4
38. Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand: exercise and type 2 diabetes. Med Sci Sports Exerc 2000; 32: 1345-60
39. Gudat U, Berger M, Lefèbvre PJ. Physical activity, fitness and non-insulin-dependent (type II) diabetes mellitus. In: Bouchard C, Shephard RJ, Stephens T, editors. Physical activity, fitness and health. Champaign (IL): Human Kinetics, 1994: 669-83
40. Blonk MC, Jacobs MAJM, Biesheuvel EHE, et al. Influences on weight loss in type 2 diabetic patients: little long-term benefit from group behaviour therapy and exercise training. Diabet Med 1994; 11: 449-57
41. Sours NE, Frattali VP, Brand CD, et al. Sudden death associated with very low calorie weight reduction regimens. Am J Clin Nutr 1981; 34: 453-61
42. Wadden TA, Stunkard AJ, Brownell KD. Very low calorie diets: their efficacy, safety, and future. Ann Intern Med 1983; 99: 675-84
43. Wadden TA, Van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA 1990; 263: 83-5
44. Amatruda JM, Richeson JF, Welle SL, et al. The safety and efficacy of a controlled low-energy (very-low-calorie) diet in the treatment of non-insulin-dependent diabetes and obesity. Arch Intern Med 1988; 148: 873-7
45. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14: 802-23
46. Scheen AJ. Intérêts et limites de la diète protéique chez le patient obèse diabétique de type 2. Ann Endocrinol (Paris) 1999; 60: 443-50
47. Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287-93
48. Wing RR, Blair EH, Bonomi P, et al. Caloric restriction per se is a significant factor in improvement in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30-6
49. Pontiroli AE, Calderara A, Pacchioni M, et al. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease. Diabetes Metab 1993; 19: 30-5
50. Scheen AJ. Aggressive weight reduction treatment inthe management of type 2 diabetes. Diabetes Metab 1998; 23: 116-23
51. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120: 669-81
52. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25: 358-63
53. Pontiroli AE, Pizzocri P, Cristina M, et al. Laprasocopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002; 87: 3555-61
54. Pories WJ, MacDonald KG, Flickinger EG, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633-43
55. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it: an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-52
56. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg 1998; 22: 936-46
57. Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477-84
58. Long SD, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal intervention study. Diabetes Care 1993; 17: 372-5
59. MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-20
60. Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83-103
61. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 1999; 23 Suppl. 1: 47-53
62. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete Metab 1993; 19: 547-59
63. Kosmiski L, Eckel RH. Anorectic agents in non-insulin dependent diabetes mellitus. Curr Opin Endocrinol Diab 1997; 4: 36-9
64. Scheen AJ, Lefèbvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000; 16: 114-24
65. Fernandez-Lopez JA, Remesar X, Foz M, et al. Pharmacological approaches for the treatment of obesity. Drugs 2002; 62: 915-44
66. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602
67. Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73
68. Redmon JB, Raatz SK, Kwong CA, et al. Pharmacological induction of weight loss to treat type 2 diabetes. Diabetes Care 1999; 22: 896-903
69. Arnaud O, Nathan C. Antiobesity and lipid-lowering agents with antidiabetic activity. In: Bailey CJ, Flatt PR, editors. New antidiabetic drugs. London: Smith-Gordon, 1990: 133-42
70. Reaven GM. Insulin resistance, hyperinsulinemia and diabetes: contribution of benfluorex. Diabetes Metab Rev 1993; 9 Suppl. 1: S1-S72
71. Ravel D. Benfluorex (MediatorR) et diabète non insulinodépendant. In: Selam J-L, editor. Journées de Diabétologie de l'Hôtel-Dieu. Paris: Flammarion Médecine-Sciences, 1997: 335-44
72. Bianchi R, Bongers V, Bravenboer B, et al. Effects of benfluorex on insulin resistance and lipid metabolism in obese Type II diabetic patients. Diabetes Care 1993; 16: 557-9
73. Velussi M, Monte AD, Cernigoi AM. Therapeutic benefit of benfluorex in type II diabetic patients on diet regimen alone. J Diabetes Complications 1996; 10: 261-6
74. Stucci N, de Gregoris P, Lavielle R, et al. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. J Diabetes Complications 1996; 10: 267-73
75. Roger P, Auclair J, Drain P. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. J Diabetes Complications 1999; 13: 62-7
76. Pontiroli AE, Pacchioni M, Piatti PM, et al. Benfluorex in obese noninsulin dependem diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab 1996; 81: 3727-32
77. Leutenegger M, Bauduceau B, Brun JM, et al. Added benfluorex in obese insulin-requiring type 2 diabetes. Diabetes Metab 1998; 24: 55-61
78. Scheen AJ, Ernest Ph. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab (Paris) 2002; 28: 437-45
79. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093-124
80. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-25
81. Van Gaal LF, Pfeiffer FW. The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001; 25 Suppl. 4: S24-8
82. Heath MJ, Chong E, Weinstein SP, et al. Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A308
83. Shepherd G, Fitchet M, Kelly F. Sibutramine: a meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (> 5.5 mmol/1) [abstract]. Int J Obes 1997; 21 Suppl. 2: S54
84. Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-12
85. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-87
86. Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957-60
87. Serrano-Rios M. Mechionda N, Moreno Carretero E, et al. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabetic Med 2002; 19: 119-24
88. Rissanen A, for the Finnish Multicentre Group. Sibutramine in the treatment of obese type II diabetics [abstract]. Int J Obes 1999; 23 Suppl. 5: S63
89. McNulty SJ, Ur E, Williams G, et al. A randomised trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125-31
90. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55
91. McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-9
92. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-73
93. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42
94. O'Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1-81
95. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes 2001; 25: 1713-21
96. Rosenfalck AM, Hendel H, Rasmussen MH, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002; 4: 19-28
97. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6
98. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-54
99. Scheen AJ. Prévention du diabète de type 2 chez le sujet obèse: premiers résultats avec l'orlistat dans l'étude XENDOS. Rev Med Liège 2002; 57: 617-21
100. Kelley DE, Jneidi M. Orlistat in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2002; 3: 599-605
101. Keating GM, Jarvis B. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drugs 2001; 61: 2107-19
102. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-94
103. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8
104. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003; 5: 180-8
105. Deerochanawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A433
106. Bonnici F. Effect of orlistat on glycemic control and body weight in overweight or obese South African patients with type 2 diabetes [abstract]. Diabetes 2002; 51 Suppl. 2: A412-3
107. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415-22
108. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-41
109. Jacob S, Gomis R, Miles JM. Effect of orlistat on glycemic control in patients on or near maximal doses of oral anti-diabetic (OAD) medications [abstract]. Diabetes 2002; 51 Suppl. 2: A413
110. De Fronzo R, Pi-Sunyer FX. Effect of orlistat in patients with type 2 diabetes at differing baseline HbAlc levels [abstract]. Diabetes 2002; 51 Suppl. 2: A412
111. Rissanen A, Hollander P. Effect of orlistat on insulin resistance in patients with type 2 diabetes with baseline HbA 1c levels > 8% [abstract]. Diabetes 2002; 51 Suppl. 2: A413
112. Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303-8
113. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997: 54: 355-68
114. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
115. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909-33
116. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542-4
117. American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-8
118. Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225-36
119. Groop LC. Sulfonylureas and NIDDM Diabetes Care 1992; 15: 737-54
120. Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al., editors. International textbook of diabetes mellitus. 2nd ed. Chichester: J Wiley, 1997: 817-40
121. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
122. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17: 411-25
123. Owens DR. Repaglinide: prandial glucose regulator. A new class of oral antidiabetic drug. Diabet Med 1998; 15 Suppl. 4: S28-36
124. Dunn CJ, Faulds D. Nateglinide. Drugs 2000; 60: 607-15
125. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
126. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49
127. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110
128. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89-131
129. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33-7
130. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
131. Nagi D, Yudkin J. Effect of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-9
132. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 1994; 19: 920-6
133. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33
134. Genuth S. Implications of the United Kingdom Prospective Diabetes Study for patients with obesity and type 2 diabetes. Obes Res 2000; 8: 198-201
135. Paolisso G, Amato L, Eccellente R. et al. Effect of metformin on food intake in obese subjects. Eur J Clin invest 1998; 28: 441-6
136. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-12
137. Fritsche A, Schmülling RM, Haring HU, et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000; 37: 13-8
138. Hermann LS, Kalen J, Katzman P, et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001; 3: 428-34
139. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45
140. Scheen AJ. Clinical efficacy of acarbose in the treatment of diabetes: a critical review of controlled trials. Diabetes Metab 1998; 24: 311-20
141. Holman RR, Cull CA, Turner RC, et al. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-4
142. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56
143. Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-73
144. Delgado H, Lehmann T, Bobbioni-Harsch E, et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200
145. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7
146. Screen AJ. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003; 63 (10): 933-51
147. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type lI diabetes. Diabetes 1996; 45: 1661-9
148. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14
149. Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568-77
150. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37
151. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-43
152. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72
153. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702
154. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-409
155. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803
156. Scheen AJ. Glitazones et prise de poids. Ann Endocrinol (Paris) 2002; 63: S41-4
157. Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentrations but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470-4
158. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93
159. Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-71
160. Katoh S, Hata S, Matsushima M, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy: a randomized controlled trial. Metabolism 2001; 50: 414-7
161. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obesity Res 2002; 10: 1008-15
162. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91
163. Campbell IA. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000; 60: 1017-28
164. Iavicoli M, Cucinotta D, De Mattia G, et al. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents. Diabet Med 1988; 5: 849-55
165. Scheen AJ. Insulin therapy in the treatment of NIDDM. IDF Bull 1996; 41: 16-8
166. Randeree HA, Omar MAK, Motala AA, et al. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1993; 16: 1258-63
167. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67
168. Buse J. Combining insulin and oral agents. Am J Med 2000; 108 Suppl. 6A: 23S-32S
169. Herman LS. Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 2000; 17: 283-94
170. Yki-Järvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130: 389-96
171. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-12
172. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928-35
173. Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-32
174. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32
175. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-7
176. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51-61
177. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomised controlled trial. Diabetes Care 2003; 26: 784-90
178. Riddle MC. Pramlintide: an agent for glycemic control plus weight control. Diabetes Technol Ther 2002; 4: 63-5
179. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81
180. Yki-Järvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000; 60: 975-83
181. Kjeldsen SE, Os I, Farsang C, et al. Treatment of hypertension in patients with type-2 diabetes mellitus. J Hypertens 2000; 18: 1345-56
182. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001; 135: 1079-83
183. Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997; 5: 425-33
184. Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002; 112 Suppl. 8A: 19S-26S
185. Grant RW, Cagliero E, Murphy-Sheehy P, et al. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002; 112: 603-9
186. Scheen AJ, Van Gaal L, for the OCAPI Team. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI survey [abstract]. Diabetologia 2002; 45 Suppl. 2: A63
187. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension 2001; 37: 1053-9
188. Parving HH. Hypertension and diabetes: the scope of the problem. Blood Press 2001; 10 Suppl. 2: 25-31
189. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Lancet 1998; 351: 1755-62
190. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
191. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microavascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 713-20
192. Yusuf S, Gerstein H, Hoogweff B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-5
193. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
194. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10
195. Pyörälä K, Pedersen TE, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20
196. Heart Protection Study Collaborative Group MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-23
197. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8
198. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9
199. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9 Suppl. 4: 326S-34S
200. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58